Stem cell program wins key court ruling, poised to issue grants
By San Francisco Chronicle,
San Francisco Chronicle
| 11. 30. 2005
California's embattled Proposition 71 stem cell program took a big step Tuesday toward overcoming lawsuits that have blocked its first grants from being issued.
Alameda County Superior Court Judge Bonnie Sabraw denied essentially every legal argument brought by the plaintiffs in litigation alleging that Prop. 71 violated the state Constitution because it would allow taxpayer-backed bond revenues to be distributed without direct legislative control.
The Prop. 71 program was created by state voters in November 2004 with authority to disperse $3 billion in grants during the next 10 years, mostly intended to advance controversial embryonic stem cell research. A state agency called the California Institute for Regenerative Medicine has been created and based in San Francisco.
Lawsuits challenging the institute's plans were filed by taxpayer groups and an anti-abortion bioethics organization, frustrating research advocates who say stem cells are key to creating a radical new kind of cell-based medicine that is potentially capable of curing such maladies as Parkinson's disease, diabetes and spinal cord injuries.
Now, the program's leadership hopes to move forward by January with a stopgap funding plan...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...